The IL11 Knockout NCI-H1703 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human lung squamous cell carcinoma cell line NCI-H1703. This product provides a loss-of-function model for the interleukin 11 (IL11) gene, enabling the study of IL11-mediated signaling pathways in a disease-relevant cellular context. The heterogeneous pool of edited cells captures a range of genetic disruptions at the target locus, facilitating robust assessment of IL11-dependent phenotypes without clonal selection bias.
The NCI-H1703 cell line was established from a primary lung squamous cell carcinoma and serves as a well-characterized epithelial model for this non-small cell lung cancer subtype. These adherent cells retain key features of malignant lung epithelial cells, including constitutive activation of oncogenic pathways and responsiveness to microenvironmental cues. Their use as the host for IL11 knockout provides a physiologically relevant system to dissect the role of IL11 signaling in squamous cell carcinoma biology.
Interleukin 11 signals through a receptor complex comprising IL11RA and gp130 (IL6ST). Ligand binding activates receptor-associated JAK1 and JAK2, leading to STAT3 phosphorylation and nuclear translocation, which regulates downstream targets such as SOCS3, BCL2, CCND1, and MYC. IL11 expression is stimulated by upstream factors including TGF-??, IL-1, TNF-??, and mechanical stress, integrating diverse inflammatory and fibrotic inputs. The canonical JAK/STAT3 cascade, together with cross-talk to MAPK/ERK signaling, drives IL11-mediated cell proliferation, survival, and inflammation. Disruption of IL11 prevents functional receptor complex assembly, thereby abolishing STAT3-dependent transcriptional programs.
In the context of non-small cell lung cancer, IL11 has been implicated in promoting tumor growth, survival, and a pro-inflammatory tumor microenvironment. The IL11 Knockout NCI-H1703 Polyclonal Cells allow direct interrogation of IL11-dependent oncogenic mechanisms, such as STAT3-mediated transcriptional programs that drive cyclin D1 expression and cell cycle progression. By disrupting this axis, researchers can evaluate the dependency of squamous carcinoma cells on autocrine and paracrine IL11 signaling, and assess the potential of targeting the IL11 pathway as a therapeutic strategy. This model also facilitates studies of cross-talk between IL11 signaling and other oncogenic drivers prevalent in lung cancer.
These polyclonal knockout cells are suitable for a wide array of experimental approaches, including western blot analysis of STAT3 phosphorylation, RT-qPCR quantification of IL11 transcript ablation, transcriptomic profiling via RNA-seq to identify downstream gene network perturbations, and functional assays such as proliferation (MTT) and transwell migration. They serve as a powerful tool for drug target validation, mechanistic dissection of gp130 cytokine signaling, and exploration of the tumor microenvironment. For additional information or to inquire about custom cell engineering services, please contact Ascent Research.
